Search results
Found 30896 matches for
The Aspirin Esomeprazole Chemoprevention Trial (AspECT) is to our knowledge one of the largest cancer prevention trials using aspirin and acid suppression in the world. In total 2557 patients with a common precancerous change in their oesophagus, called Barrett’s oesophagus, were followed up for an average of 9 years resulting in over 20,000 life-years of follow up. After informed written consent, patients were randomly allocated to four different combinations; Low acid suppression alone, High acid suppression alone, low acid suppression with 300mg aspirin and high acid suppression with 300mg aspirin. We wanted to see if we could prevent progression to local cancer/cancer in-situ (high grade dysplasia), invasive cancer or prevent death by all causes both cancer and non-cancer.
Srinivasa Rao Rao
MBBS, MS (res), DPhil, AFHEA Srinivasa Rao Rao - Senior Researcher in Cancer Genomics
Adrian Kendal
MA (Oxon.) BMBCh, DPhil (Oxon.), FRCS (Ortho.) Adrian Kendal - Honorary Senior Clinical Lecturer
Jolet Mimpen
DPhil, MSc, BSc (Hons) Jolet Mimpen - Senior Research Fellow in Musculoskeletal Tissue Biology
Frank Penkava
Frank Penkava - Wellcome Trust Early Career Fellow in Immunology of Spondyloarthritis
Laura Coates
MBChB, MRCP, PhD Laura Coates - NIHR Research Professor and Senior Clinical Research Fellow
Beata Giglio
Beata Giglio - Programme Manager for Functional Genomics Cluster / Project Manager for Health Economics and Outcomes Research Group
Christopher Buckley
Christopher Buckley - Kennedy Professor of Translational Rheumatology and Director of Clinical Research
Stephanie Dakin
PhD BVetMed FRCVS PGCert TLHE FHEA Stephanie Dakin - Professor of Musculoskeletal Sciences
Abhishek Puthenveetil
Abhishek Puthenveetil - Postdoctoral Research Assistant in Immuno-Oncology
Greg Halliwell
Greg Halliwell - NIHR Pre-Doctoral Fellow Medical Statistician